ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 98 filers reported holding ALDEYRA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 2.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,755,126 | -20.6% | 412,444 | -0.3% | 0.00% | 0.0% |
Q2 2023 | $3,470,742 | +308.9% | 413,676 | +383.9% | 0.00% | – |
Q1 2023 | $848,876 | +42.1% | 85,486 | -0.4% | 0.00% | – |
Q4 2022 | $597,245 | +30.4% | 85,811 | -0.0% | 0.00% | – |
Q3 2022 | $458,000 | +27.2% | 85,821 | -4.8% | 0.00% | – |
Q2 2022 | $360,000 | -81.6% | 90,152 | -79.5% | 0.00% | – |
Q1 2022 | $1,953,000 | +7.5% | 439,453 | -3.2% | 0.00% | – |
Q4 2021 | $1,816,000 | -56.7% | 454,115 | -5.0% | 0.00% | -100.0% |
Q3 2021 | $4,198,000 | -26.3% | 478,058 | -5.0% | 0.00% | 0.0% |
Q2 2021 | $5,699,000 | +431.6% | 503,064 | +457.7% | 0.00% | – |
Q1 2021 | $1,072,000 | +112.7% | 90,202 | +23.0% | 0.00% | – |
Q4 2020 | $504,000 | -9.8% | 73,364 | -2.7% | 0.00% | – |
Q3 2020 | $559,000 | +170.0% | 75,424 | +52.0% | 0.00% | – |
Q2 2020 | $207,000 | -68.1% | 49,622 | -81.1% | 0.00% | – |
Q1 2020 | $649,000 | -56.4% | 262,816 | +2.6% | 0.00% | – |
Q4 2019 | $1,489,000 | +9.6% | 256,276 | -0.6% | 0.00% | – |
Q3 2019 | $1,359,000 | -23.5% | 257,862 | -12.9% | 0.00% | – |
Q2 2019 | $1,777,000 | -28.9% | 296,129 | +6.9% | 0.00% | -100.0% |
Q1 2019 | $2,501,000 | +15.6% | 276,926 | +6.2% | 0.00% | 0.0% |
Q4 2018 | $2,164,000 | -23.6% | 260,761 | +27.1% | 0.00% | 0.0% |
Q3 2018 | $2,831,000 | +86.2% | 205,082 | +7.2% | 0.00% | – |
Q2 2018 | $1,520,000 | +321.1% | 191,275 | +297.2% | 0.00% | – |
Q1 2018 | $361,000 | +48.0% | 48,151 | +34.3% | 0.00% | – |
Q4 2017 | $244,000 | +96.8% | 35,861 | +107.7% | 0.00% | – |
Q3 2017 | $124,000 | +77.1% | 17,267 | +15.1% | 0.00% | – |
Q2 2017 | $70,000 | -6.7% | 14,999 | 0.0% | 0.00% | – |
Q1 2017 | $75,000 | -2.6% | 14,999 | +4.7% | 0.00% | – |
Q4 2016 | $77,000 | -23.0% | 14,324 | +11.5% | 0.00% | – |
Q3 2016 | $100,000 | +42.9% | 12,846 | +3.9% | 0.00% | – |
Q2 2016 | $70,000 | +37.3% | 12,366 | +0.7% | 0.00% | – |
Q1 2016 | $51,000 | -38.6% | 12,286 | 0.0% | 0.00% | – |
Q4 2015 | $83,000 | +16.9% | 12,286 | 0.0% | 0.00% | – |
Q3 2015 | $71,000 | -17.4% | 12,286 | +10.6% | 0.00% | – |
Q2 2015 | $86,000 | – | 11,106 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 908,488 | $6,232,000 | 2.88% |
Knoll Capital Management, LLC | 569,405 | $3,906,000 | 2.66% |
Mesirow Financial Investment Management, Inc. | 64,698 | $443,828,000 | 1.40% |
Ghost Tree Capital, LLC | 650,000 | $4,459,000 | 0.99% |
Johnson & Johnson Innovation - JJDC, Inc. | 594,834 | $4,081,000 | 0.53% |
Perceptive Advisors | 6,285,458 | $43,118,000 | 0.46% |
Affinity Asset Advisors, LLC | 100,000 | $686,000 | 0.36% |
ACUTA CAPITAL PARTNERS, LLC | 192,500 | $1,321,000 | 0.36% |
Avidity Partners Management LP | 1,435,000 | $9,844,000 | 0.32% |
APOGEM CAPITAL LLC | 55,821 | $383,000 | 0.26% |